Assessment of non-myelotoxic agents as a preparatory regimen for hematopoietic stem cell gene therapy
Human Cell · 2024
DOI: 10.1007/s13577-024-01130-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Cell, 2024. Verfasst von Mehmet Emin Şeker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Sciences, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkey. Hauptthemen laut MEDLINE: Cyclams, Benzylamines, Hematopoietic Stem Cell Transplantation, Granulocyte Colony-Stimulating Factor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Scientific and Technological Research Council of Turkey (TÜBİTAK), Hacettepe Üniversitesi, European Union Framework Program 7.
Abstract (Originalsprache)
RAG2 deficiency is characterized by a lack of B and T lymphocytes, causing severe lethal infections. Currently, RAG2 deficiency is treated with a Hematopoietic Stem Cell transplantation (HSCT). Most conditioning regimens used before HSCT consist of alkylating myelotoxic agents with or without irradiation and affect growth and development of pediatric patients. Here, we developed a non-myelotoxic regimen using G-CSF, VLA-4I or AMD3100. These agents are known HSC mobilizers or affect bone marrow (BM) permeability and may support the homing of HSCs to the BM, without inducing major side effects. Female Rag2-/- mice were pre-treated with Busulfan (BU), G-CSF, VLA-4I or AMD3100 and transplanted with male BM cells transduced with a lentiviral vector carrying codon optimized human RAG2 (RAG2co). Peripheral blood cell counts increased significantly after G-CSF, VLA-4I and AMD3100 treatment, but not after BU. Reconstitution of PB lymphocytes was comparable for all groups with full immune reconstitution at 6 months post transplantation, despite different methods of conditioning. Survival of mice pre-treated with non-myelotoxic agents was significantly higher than after BU treatment. Here, we show that the non-myelotoxic agents G-CSF, VLA-4I, and AMD3100 are highly effective as conditioning regimen before HSC gene therapy and can be used as an alternative to BU.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell Sciences, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkey.
- Center for Stem Cell Research and Development, Hacettepe University, Ankara, Turkey.
- Department of Hematology, Erasmus University Rotterdam, Rotterdam, The Netherlands.
- Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam Neuroscience, 1081 HV, Amsterdam, The Netherlands.
- Department of Integrative Neurophysiology, Center for Neurogenomics and Cognitive Research, Vrije Universiteit, 1081 HV, Amsterdam, The Netherlands.
- Department of Stem Cell Sciences, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkey. fatima.aerts@hacettepe.edu.tr.
Förderung
- Scientific and Technological Research Council of Turkey (TÜBİTAK)
- Hacettepe Üniversitesi
- European Union Framework Program 7
Zitieren
APA
Şeker, M. E., Erol, Ö. D., Pervin, B., Wagemaker, G., van Til, N. P., & Aerts-Kaya, F. (2024). Assessment of non-myelotoxic agents as a preparatory regimen for hematopoietic stem cell gene therapy. Human Cell. https://doi.org/10.1007/s13577-024-01130-6
Vancouver
Şeker ME, Erol ÖD, Pervin B, Wagemaker G, van Til NP, Aerts-Kaya F. Assessment of non-myelotoxic agents as a preparatory regimen for hematopoietic stem cell gene therapy. Human Cell. 2024. doi:10.1007/s13577-024-01130-6
BibTeX
@article{eker2024,
author = {Şeker, Mehmet Emin and Erol, Özgür Doğuş and Pervin, Burcu and Wagemaker, Gerard and van Til, Niek P and Aerts-Kaya, Fatima},
title = {Assessment of non-myelotoxic agents as a preparatory regimen for hematopoietic stem cell gene therapy},
journal = {Human Cell},
year = {2024},
doi = {10.1007/s13577-024-01130-6}
}
EUVIMED